Patents Assigned to Quest Diagnostics Investments LLC
-
Publication number: 20220215901Abstract: The present disclosure describes a sequencing system configured to identify structural variants in mitochondrial DNA. Variant callers configured to identify variants in linear genomes (e.g., those found in chromosomes) can fail to properly identify structural variants in mitochondrial DNA. The system and methods can identify structural variants in next generation sequencing data collected from circular, mitochondrial DNA.Type: ApplicationFiled: May 26, 2020Publication date: July 7, 2022Applicant: Quest Diagnostics Investments LLCInventor: Anindya Bhattacharya
-
Publication number: 20220196665Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.Type: ApplicationFiled: March 14, 2022Publication date: June 23, 2022Applicant: Quest Diagnostics Investments LLCInventor: Maher ALBITAR
-
Patent number: 11360098Abstract: Provided are methods for the detection or quantitation of amyloid beta. In a particular aspect, provided herein are methods for detecting amyloid beta or fragments thereof by mass spectrometry. In another aspect, provided herein are methods for determining the ratio of amyloid beta 42 (A?42) to amyloid beta 40 (A?40). In another aspect, provided herein are methods for diagnosis or prognosis of Alzheimer's disease or dementia.Type: GrantFiled: September 27, 2016Date of Patent: June 14, 2022Assignee: Quest Diagnostics Investments LLCInventors: Diana Tran, Darren Weber, Nigel Clarke
-
Patent number: 11345964Abstract: Truncation variants of BCR-ABL mRNA that produces BCR-ABL proteins with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is described. Vectors for expressing the truncated gene products are described as well as recombinant cells that express the truncated gene products from cDNA constructs. Also provided are methods compositions and kits for detecting the BCR-ABL truncation variants. Also provided are methods for determining the prognosis of a patient diagnosed as having myeloproliferative disease, and methods for predicting the likelihood for resistance to a treatment with tyrosine kinase inhibitor in a patient diagnosed as having myeloproliferative disease. Additionally, methods for screening BCR-ABL tyrosine kinase domain inhibitors which rely on the recombinant cells are also disclosed.Type: GrantFiled: October 5, 2018Date of Patent: May 31, 2022Assignee: Quest Diagnostics Investments, LLCInventors: Maher Albitar, Wanlong Ma
-
Publication number: 20220163494Abstract: Provided are methods for detecting chromogranin A by mass spectrometry. In another aspect, provided herein are methods for quantitating chromogranin A by mass spectrometry. In another aspect, provided herein are methods for prognosis of or measuring the size of neuroendocrine tumors by mass spectrometry.Type: ApplicationFiled: January 24, 2022Publication date: May 26, 2022Applicant: Quest Diagnostics Investments LLCInventors: Darren Weber, Michael P. Caufield, Michael McPhaul, Scott Goldman, Nigel Clarke
-
Publication number: 20220145367Abstract: The present disclosure provides methods for determining whether a patient exhibiting pneumonia-like symptoms will benefit from treatment with therapeutic agents that inhibit Legionella sp. These methods are based on detecting Legionella sp. and/or Legionella pneumophila in a biological sample. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: January 30, 2020Publication date: May 12, 2022Applicant: Quest Diagnostics Investments LLCInventor: Erik P. Johnson
-
Publication number: 20220098679Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.Type: ApplicationFiled: October 13, 2021Publication date: March 31, 2022Applicant: Quest Diagnostics Investments LLCInventors: Heather R. SANDERS, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
-
Publication number: 20220090049Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.Type: ApplicationFiled: December 7, 2021Publication date: March 24, 2022Applicant: Quest Diagnostics Investments LLCInventors: Heather SANDERS, Hai-Rong Li
-
Patent number: 11278904Abstract: A container for a specimen includes a container configured to receive a specimen for evaluation, a first label disposed on the container and having identifying information, and a second label disposed on the container so as to entirely cover at least all perimeter edges of the first label. The second label includes a viewing portion that allows for evaluation of the specimen and an identification portion configured to receive identifying information. Methods for using the container for a specimen are also disclosed.Type: GrantFiled: July 27, 2018Date of Patent: March 22, 2022Assignee: Quest Diagnostics Investments LLCInventors: Daniel E. Carty, Fredric Solomon
-
Patent number: 11275088Abstract: A splice variant of bcr-abl mRNA that produces BCR-ABL protein with a truncated C-terminus and its role in resistance to treatment with kinase inhibitors is disclosed. Vectors for expressing the truncated gene product are provided as well as recombinant cells that express the truncated gene product from a cDNA construct. Also provided are methods compositions and kits for detecting the BCR-ABL splice variant. Additionally, methods for screening BCR-ABL kinase domain inhibitors which rely on the recombinant cells and methods of predicting likelihood for resistance of a CML patient with a BCR/ABL translocation respond to treatment with one or more BCR-ABL kinase inhibitors are also disclosed.Type: GrantFiled: August 10, 2020Date of Patent: March 15, 2022Assignee: Quest Diagnostics Investments LLCInventor: Maher Albitar
-
DETECTION OF GENE FUSIONS BY INTRAGENIC DIFFERENTIAL EXPRESSION (IDE) USING AVERAGE CYCLE THRESHOLDS
Publication number: 20220042110Abstract: Described herein are methods and kits for detecting the presence or absence of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5? portion of a target gene relative to the 3? region of the target gene. The average expression of the 5? portion of the target gene is compared with the average expression of the 3? portion of the target gene to determine an intragenic differential expression (IDE). The IDE can then be used to determine if a dysregulation or a particular disease (or susceptibility to a disease) is present or absent in a subject or sample.Type: ApplicationFiled: August 16, 2021Publication date: February 10, 2022Applicant: Quest Diagnostics Investments LLCInventor: Shih-Min CHENG -
Publication number: 20220042971Abstract: Methods are described for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.Type: ApplicationFiled: April 19, 2021Publication date: February 10, 2022Applicant: Quest Diagnostics Investments LLCInventors: Dov Shiffman, Carmen Tong, James J. Devlin, Michael J. McPhaul
-
Publication number: 20220033901Abstract: Described herein are methods, compositions and kits directed to amplification of nucleic acids suitable for both next generation sequencing (NGS) and a second round of sequencing as validation, such as Sanger sequencing.Type: ApplicationFiled: August 9, 2021Publication date: February 3, 2022Applicant: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li, Feras Hantash, Frederic Waldman
-
Patent number: 11231401Abstract: Provided are methods for detecting chromogranin A by mass spectrometry. In another aspect, provided herein are methods for quantitating chromogranin A by mass spectrometry. In another aspect, provided herein are methods for prognosis of or measuring the size of neuroendocrine tumors by mass spectrometry.Type: GrantFiled: March 15, 2019Date of Patent: January 25, 2022Assignee: Quest Diagnostics Investments LLCInventors: Darren Weber, Michael P. Caufield, Michael McPhaul, Scott Goldman, Nigel Clarke
-
Publication number: 20220010378Abstract: The present invention provides methods for analyzing large nucleic acids including chromosomes and chromosomal fragments. In one aspect, the present invention provides a method of nucleic acid analysis comprising the steps of (a) obtaining a sample of nucleic acid comprising at least one chromosome or fragment greater than about 1,000 base pairs in length and containing a target region; (b) creating an emulsion in which each drop of the emulsion contains an average of between about 0-2, 0-1.75, 0-1.5, 0-1.0, 0-0.75, 0-0.5, or fewer chromosomes or fragments of step (a), (c) performing emulsion PCR, (d) quantifying the number of emulsion droplets containing amplified nucleic acid from the target region; (e) calculating the ratio of droplets containing amplified nucleic acid from the target region to total droplets; and (f) comparing the ratio of step (e) to a reference ratio representing a known genotype.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Applicant: Quest Diagnostics Investments LLCInventor: Charles M. STROM
-
Patent number: 11193120Abstract: The invention provides methods for isolating RNA from the soluble fraction of urine. The methods can be used for detecting the presence or absence of an RNA, or quantifying the amount of an RNA. The methods are useful for diagnosing an individual suspected of having a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine. The methods are also useful for prognosing an individual diagnosed with a disease by detecting the level of RNA associated with the disease in the soluble fraction of urine.Type: GrantFiled: November 22, 2019Date of Patent: December 7, 2021Assignee: Quest Diagnostics Investments LLCInventors: Heather Sanders, Hai-Rong Li
-
Publication number: 20210363569Abstract: The present invention relates to methods for the diagnosis of bacterial vaginosis based on an analysis of a patient sample. For example, patient test samples are analyzed for the presence or absence of one or more lactobacilli and two or more pathogenic organisms. The presence or absence of one or more lactobacilli and two or more pathogenic organisms may be detected using PCR analysis of nucleic acid segments corresponding to each target organism. The quantity of the target organisms can then be used to determine a score which is indicative of a diagnosis of bacterial vaginosis.Type: ApplicationFiled: June 7, 2021Publication date: November 25, 2021Applicant: Quest Diagnostics Investments LLCInventors: Erik P. Johnson, Dale A. Schwab
-
Patent number: 11155877Abstract: Provided herein are methods and compositions for detection of a nucleic acid target in a sample. The methods and compositions use primer directed amplification in conjunction with nucleic acid fragmentation. The methods have high sensitivity even in the presence of a large amount of non-target nucleic acid. Also provided are oligonucleotides and kits useful in the method. Exemplary nucleic acid targets are those with mutant gene sequence such as mutant sequence of the EGFR, APC, TMPRSS2, ERG and ETV1 genes.Type: GrantFiled: October 19, 2018Date of Patent: October 26, 2021Assignee: Quest Diagnostics Investments LLCInventors: Heather R. Sanders, Kevin Z. Qu, Charles M. Strom, Richard A. Bender
-
Publication number: 20210324468Abstract: The present technology relates to methods for determining whether a patient having thyroid nodules with indeterminate cytology will benefit from diagnostic surgery, e.g., lobectomy. These methods are based on screening a patient's thyroid nodules and detecting alterations in target nucleic acid sequences corresponding to a specific set of thyroid cancer-related genes. Kits for use in practicing the methods are also provided.Type: ApplicationFiled: June 29, 2021Publication date: October 21, 2021Applicant: Quest Diagnostics Investments LLCInventors: Shih-Min CHENG, Joseph J. CATANESE, Andrew GRUPE, Feras HANTASH, Frederic M. WALDMAN, Kevin QU
-
Publication number: 20210313011Abstract: The systems and methods discussed herein can calculate sequencing statistics such as coverage depth for sequencing data. The present solution can determine variant frequencies and identify clinically relevant variants. The present solution can read BAM and VCF input files and Phred scaled quality scores. The present solution can select relatively high quality reads based on the quality scores and can calculate reference and alternative allele counts for SNPs, insertions and deletions (INDELs), and structural variants.Type: ApplicationFiled: October 16, 2019Publication date: October 7, 2021Applicant: Quest Diagnostics Investments LLCInventors: Anindya Bhattacharya, Anna Gerasimova, Quoclinh Nguyen, Christopher Elzinga, Edward Moler